- 95.5% iORR, Asandeutertinib Sets New Benchmark in 1L EGFR-mutated NSCLC Brain Mets
- A2 Biotherapeutics Presents Safety and Efficacy Data from EVEREST-2 Clinical Study, Including Update on the First Complete Response to CAR T-Cell Therapy in a Patient with NSCLC
- Agenus Presents Ph 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma
- Alpha Tau Announces Strong OS Results from Alpha DaRT® Pancreatic Cancer
- Astellas Presents Data on Long-Term Outcomes and Clinical Use of Portfolio Across Disease Stages
- Avenzo Therapeutics Presents Updated Results from Ph 1/2 Study of AVZO-021
- BeOne Medicines Announces Ph 3 HERIZON-GEA Data Published in NEJM and Presented
- BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data
- BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data
- BMS Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. SOC in Relapsed or Refractory Multiple Myeloma
- Callio Therapeutics to Present Ph 1 Trial Design of CLIO-8221
- Cardiff Oncology Announces Positive Results from Randomized, Controlled Ph 2 Trial of Onvansertib in 1L RAS-Mutated mCRC
- Celcuity’s Gedatolisib Combos Doubled Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in PIK3CAm Cohort of Ph 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer
- Cellectar Biosciences Highlights Compelling New Efficacy Data from Ph 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
- Cogent Biosciences Announces Detailed Clinical Data from PEAK Ph 3 Trial with Bezuclastinib in Combination with Sunitinib in GIST
- D3 Bio Presents 1L Data for Elisrasib (D3S-001) in 1L NSCLC
- Dizal Announces Ph 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemo in 1L EGFR Exon 20 Insertion Mutation-Positive NSCLC
- Eikon Therapeutics Presents Data on Clinical-Stage Programs
- Encouraging Global Ph 2 Ivonescimab Data in 1L Metastatic Colorectal Cancer Presented
- Exelixis Announces Results from Subgroup Analysis of Ph 3 CABINET Pivotal Trial Evaluating CABOMETYX in Non-Functional and Functional Neuroendocrine Tumors
- Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year OS and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
- Global Data for BioNTech and Bristol Myers Squibb’s Pumitamig Shows Encouraging Efficacy in Patients with NSCLC in ROSETTA Lung-02 Trial
- HARMONi-6 Demonstrates Significant OS Benefit with Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in 1L sq-NSCLC
- Hengrui Pharma presented more than 90 studies spanning multiple tumor types and therapeutic modalities
- IN8bio Presents Updated OS Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed GBM
- IDEAYA Biosciences and Servier Provide Complete Data from Ph 2/3 OptimUM-02 Trial of the Darovasertib Combination in 1L HLA*A2:01 Negative Metastatic Uveal Melanoma
- Imfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death in EMERALD-3 Ph 3 trial
- Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy
- Immuneering Presents Compelling 17.3-Month mOS and Favorable Tolerability with Atebimetinib + Chemo in 1L Pancreatic Cancer Patients
- Immunocore presents updated Ph 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
- ImPact Biotech Presents Updated Data from Ph 1 Trial of Padeliporfin VTP in LA-PDAC and Ph 3 ENLIGHTED Trial in LG-UTUC
- Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged PFS, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
- Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) in 1L Advanced NSCLC
- Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant NSCLC
- ITM Announces Ph 3 COMPETE Patient-Reported QoL Data with n.c.a.¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus
- Johnson & Johnson’s Ph 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death
- Kelonia Therapeutics Presents Updated First-in-Human Data from Ph 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy
- Kelun-Biotech Presents Pivotal Ph 2 Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC
- Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
- Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI Data in Multiple Myeloma
- Lifyorli OS Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
- Lilly’s Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
- Lytix Biopharma Reports Ph 2 Data in Melanoma and TNBC for Ruxotemitide (LTX-315) in Combination with Pembrolizumab
- Mabwell Announces Latest Clinical Data on 9MW2821
- Menarini Group Presents New Data from the Ph 1b/2 ELEVATE Study of Elacestrant + Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer
- Merck Highlighted New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research
- Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
- Molecular Partners presents DLL3-Targeting Radio-DARPin MP0712; Dosing Patients in Ph 1
- Neoadjuvant Anbenitamab Improves Pathologic Complete Response in Ph 3 HER2+ve Early Breast Cancer Trial
- New Clinical Data for Izalontamab Brengitecan and Novel ADC Pipeline Presented
- New TECVAYLI (teclistamab) data demonstrate superior PFS and OS versus SOC as early as first relapse in multiple myeloma
- Oncolytics Biotech Presents Data Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
- Ono Pharma Announces New Data from Ph 2 Study of ONO-4578 (EP4 antagonist) in Certain Gastric Cancers
- Ontada Study Examines Real-World Use of GLP‑1 Receptor Agonists and Survival Outcomes Across Common Cancers in U.S. Community Oncology
- Orion Pharma announces first results from Ph 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours
- OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Ph 2 Trial with Tedopi in Recurrent Ovarian Cancer
- Pfizer’s BRAFTOVI Regimen Nearly Doubles mPFS in mCRC
- Ph 2 Study of Pembrolizumab + Plinabulin and Docetaxel for Patients with Metastatic NSCLC after Failure on 1L Immune Checkpoint Inhibitor Alone or Combination Therapy
- Ph 3 HERIZON-GEA-01 Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in 1L HER2+ Locally Advanced or Metastatic GEA
- Phanes Therapeutics announces updated Ph 2 clinical trial results of spevatamig (PT886) in combination with chemotherapy in 1L metastatic PDAC
- Pliant Therapeutics Highlights FORTIFY, the Ph 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors
- Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic HSPC
- Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial
- Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors
- Results of Ph 3 OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented
- Revolution Medicines Announces Unprecedented Results from Pivotal Ph 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
- RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer
- Salubris Biotherapeutics Presents Updated Expansion Cohort Data for JK06, 5T4-Targeted Antibody Drug Conjugate
- Sapience Therapeutics Provides Positive Data Update from Ph 2 Trial of Lucicebtide Plus SOC in Patients with GBM
- Scemblix continued to show superior efficacy and favorable safety and tolerability profile at week 144 in 1L CML
- Servier Presents Extended Follow-Up Results from the Ph 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib)
- Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest PFS Reported to Date in Advanced NSCLC
- SystImmune Reports Ph 1 Data for BL-M14D1 Demonstrating Promising Activity in SCLC
- TALZENNA Plus XTANDI Improves Radiographic PFS by More Than 50% in Metastatic Prostate Cancer
- Theolytics’ Ongoing US Ph 1 OCTOPOD-IP Trial of THEO-260 in Ovarian Cancer Presented as a Trial in Progress
- Updated Data from an Oral Presentation of InnoCare’s Novel BCL2 Inhibitor Mesutoclax in MDS and AML presented